AIM ImmunoTech vs Allogene Therapeutics
AIM and ALLO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AIM and ALLO compare
Allogene Therapeutics is the larger company, worth 69 times as much as AIM ImmunoTech ($311M against $4.5M).
Allogene Therapeutics scores higher on the StockData Score (3 against 2 for AIM ImmunoTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AIM | ALLO |
|---|---|---|
| Size and price | ||
| Market cap | $4.5M | $311M |
| Share price | $0.148 | $0.900 |
| Change, 1 year | −90.6% | −23.7% |
| Change, 5 years | −99.9% | −95.2% |
| Beta (5Y) | 0.84 | 1.62 |
| Employees | – | 152 |
| StockData Score | ||
| Total score | 2 | 3 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 47.6× | – |
| P/B | 0.6× (better) | 0.8× |
| FCF yield | – | −35.0% |
| Growth | ||
| Revenue growth (TTM) | −21.5% | – |
| Revenue growth, 5Y average | −11.6% | – |
| Profitability | ||
| Operating margin | −11724% | – |
| Net margin | −15021% | – |
| Return on equity | −2382% | −49.3% (better) |
| Return on invested capital | – | −718% |
| Financial health | ||
| Debt / equity | 0.47 | – |
| Interest coverage | −9.8× (better) | −142.5× |
| Current ratio | 2.11 | 7.79 (better) |
| Altman Z-score | −51.04 | −4.92 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 3.8% | 90.5% |
| Held by insiders | 12.8% | 15.0% |
| Insider net buying, 12 months | $33.9K (better) | −$668K |
| Short interest, % of float | 3.8% | 17.5% |
Go deeper
- AIM stock overview
- AIM income statement
- AIM valuation and score
- ALLO stock overview
- ALLO income statement
- ALLO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.